streptococci

Penicillin V Potassium (Phenoxymethylpenicillin potassium salt) is an orally administered, broad-spectrum penicillin antibiotic used for treating mild to moderate infections caused by susceptible gram-positive organisms.

DuP 105 is an oxazolidinone compound and a bacterial protein synthesis inhibitor with oral activity and selective antibacterial activity against Gram-positive bacteria. It can be used to study infections caused by susceptible Gram-positive bacteria such as staphylococci and streptococci, and has shown protective effects in animal models.

Antibacterial compound 2 is a potent antimicrobial agent effective against many human veterinary pathogens, inhibiting multi-drug resistant staphylococci, enterococci and streptococci, as well as anaerobic bacteria.

Mupirocin (BRL-4910A) is a RNA synthetase inhibitor antibacterial. It has shown excellent activity against gram-positive staphylococci and streptococci.

Mupirocin calcium hydrate is an antibiotic produced by Pseudomonas fluorescens, showed a high level of activity against staphylococci and streptococci and against certain gram-negative bacteria

Sulfazamet is a sulfonamide derivative exhibiting antibacterial activity against (Streptococci sepsis).

LB 11058 is a novel injectable cephalosporin featuring a C-3 pyridyl-substituted vinyl sulfide and a C-7 2-amino-5-chloro-1,3-thiazole group. This compound exhibits exceptional activity against Streptococcus pneumoniae and demonstrates similar efficacy against β-hemolytic streptococci. The inhibition pattern for LB 11058 with S. aureus is consistent, as all isolates are inhibited under this pattern.

RNAP-σ interaction inhibitor-1 (compound 5d) acts as an inhibitor of the interaction between RNA polymerase and the sigma factor. It exhibits activity against Streptococci with a minimum inhibitory concentration (MIC) ranging from 1-2 µg/mL.

E3709 is an antibacterial agent demonstrating significant inhibitory activity against Gram-positive bacteria, including Staphylococcus aureus (MRSA), Enterococcus faecalis, streptococci, Clostridium, and Corynebacterium. E3709 can be utilized in research related to infections caused by Gram-positive bacteria.

YM 133 (IMC-XV) is a semi-synthetic macrolide antibiotic with potent bactericidal activity. It is effective against strains of staphylococci, streptococci, Bacteroides, and Clostridia that are resistant to erythromycin, josamycin, and rokitamycin (MIC≥ 100 μg/mL). Additionally, YM 133 exhibits excellent activity against macrolide-resistant strains and anaerobic bacteria, making it valuable for antibacterial research.

BB-83698 is a peptide deformylase inhibitor with potent antimicrobial against streptococci and Moraxella catarrhalis strains.

Oritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.

Isepamicin (Sch 21420) is a potent aminoglycoside antibacterial compound with enhanced efficacy against strains harboring type I 6'-acetyltransferase. Its antibacterial spectrum encompasses Enterobacteriaceae and staphylococci, while exhibiting resistance against anaerobes, Neisseriaceae, and streptococci. Moreover, Isepamicin displays a robust concentration-dependent bactericidal effect, a prolonged post-antibiotic effect lasting several hours, and is capable of inducing adaptive resistance.

Omadacycline, also known as PTK 0796 and Amadacyclin, is a novel first-in-class aminomethylcycline with potent activity against important skin and pneumonia pathogens, including community-acquired methicillin-resistant Staphylococcus aureus (MRSA), β-hemolytic streptococci, penicillin-resistant Streptococcus pneumoniae, Haemophilus influenzae, and Legionella. Omadacycline is active against strains expressing the two main forms of tetracycline resistance (efflux and ribosomal protection). The primary effect of omadacycline is on bacterial protein synthesis, inhibiting protein synthesis with a potency greater than that of tetracycline. The binding site for omadacycline is similar to that for tetracycline.

Ceftobiprole medocaril sodium (BAL5788) is a parenteral prodrug of Ceftobiprole, a pyrrolidinone cephalosporin administered intravenously. As a broad-spectrum cephalosporin, Ceftobiprole exhibits high in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococci (VRSA), and penicillin-resistant Streptococci. Additionally, it is effective in inhibiting both gram-positive and gram-negative pathogens.

Penicillin V (Phenoxymethylpenicillin) is an effective, orally-administered antibiotic with activity against Streptococci, Clostridium difficile, and Staphylococcus aureus. It holds potential for research into treatments for otitis, sinusitis, pharyngitis, and tonsillitis [1] [2] [3] [4].

Nemonoxacin (TG-873870) is an orally available non-fluorinated quinolone antibiotic with broad-spectrum antimicrobial activity against staphylococci, streptococci, and enterococci, as well as against Neisseria gonorrhoeae and Haemophilus influenzae.Nemonoxacin is used in the study of bacterial infections and community-acquired pneumonia.

Triglysin A is an antimicrobial peptide that inhibits the growth of other Streptococci [1].

Triglysin B, an antimicrobial peptide, inhibits the growth of other streptococci [1].

Ticarcillin monosodium, a semisynthetic carboxypenicillin antibacterial agent, exhibits broad-spectrum activity against gram-positive cocci such as streptococci and staphylococci. It is also effective against most gram-negative organisms, notably Pseudomonas aeruginosa. The compound is utilized in the treatment of various infections, including those of the lower respiratory tract, skin and skin structures, urinary tract, and intraabdominal infections, according to research [1] [2] [3].

Sodium hippurate (N-Benzoylglycine sodium) is used in bacterial culture applications, such as for Group B Streptococcus in beta-hemolytic streptococci, where it hydrolyzes sodium hippurate into benzoic acid.

Marcellomycin is a glycoside and quinone antibiotic. It exhibits activity against Gram-positive bacteria, with particularly strong efficacy against streptococci.

Diphenicillin (Ancillin (free acid); 2-Biphenylyl penicillin (free acid); SKF-12141 (free acid)) is a penicillin that resists Penicillinase and exhibits antibacterial activity. It shows effective activity against Gram-positive cocci. Diphenicillin is promising for research on infectious diseases caused by Gram-positive bacteria such as staphylococci, pneumococci, and group A streptococci.

Citreamicin alpha (LL-E 19085-alpha) is an antibiotic that has been evaluated for its in vitro antibacterial activity against 429 clinical isolates of Gram-positive cocci using the agar dilution method. This study included 313 strains of staphylococci and 116 strains of streptococci. Its in vitro efficacy was compared with ampicillin, amoxicillin, cephalothin, erythromycin, and vancomycin. For staphylococci, Citreamicin alpha demonstrated MIC values ranging from 0.12 to 4.0 μg/ml, and for Streptococcus pyogenes, the MIC values ranged from 0.03 to 0.12 μg/ml. Conversely, enterococci presented relative resistance, requiring 2.0 μg/ml to inhibit 64% of 62 tested strains. The antibiotic's in vitro efficacy significantly surpassed that of ampicillin, amoxicillin, cephalothin, and erythromycin, while it was comparable to or slightly less effective than vancomycin.